Inhibition of neovascularization using vegf-specific oligonucleotides
AssigneesHybridon, Inc., Children's Medical Center Corporation
InventorsGregory S. Robinson, Lois Elaine Hodgson Smith
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.
Claims8
A method of treating diabetic retinopathy comprising the step of intravitreally administrating to a subject afflicted with diabetic retinopathy a therapeutic amount of an oligonucleotide specific for vascular endothelial growth factor nucleic acid and effective in inhibiting the expression of vascular endothelial growth factor in the retina.
Dependencies are inferred from the claim text.